NOTICE:

Inhibition of HER3 by seribantumab **reduces tumor volume by 50-100% in preclinical NRG1 fusion PDX models**

Milestone data

Treatment with seribantumab reduces tumor volume by **up to 50%** in an SLC3A2-NRG1 fusion lung cancer PDX model:



Treatment with seribantumab reduces tumor volume by **up to 100%** in a CLU-NRG1 fusion ovarian cancer PDX model:



Importantly, these models are **uniquely driven by NRG1 fusions**, and contain no other known driver alterations.

Treatment with afatinib is not effective at the clinically-equivalent dose of 5 mg/kg.



PDX: patient-derived xenograft

PDX models are important laboratory research tools used to test potential therapies before they are tested in patients.

HOW TO MAKE a PDX model

Fresh tumor tissue from a donor patient is implanted into immunocompromised mice where it is able to grow.

New PDX models must be passaged over 6-12 months.



Once the models are ready, experimental therapies can be tested to evaluate their safety and efficacy in a "patient-like" tumor.

BENEFITS OF PDX models

PDX models are highly effective in maintaining the characteristics of the patient's original tumor, including its genomic signature.

Treatment outcomes in PDX models have been shown to accurately replicate clinical outcomes in patients.

Up to **87%** correlation in therapeutic outcomes[1]



[1] Izumchenko et al., Ann Oncol. 2017 Oct; 28(10): 2595-2605.

A tumor's genome defines a unique "fingerprint".

PDX models AND genomic driver alterations

When a genomic driver alteration **like an NRG1 fusion** is found in a tumor's genomic "fingerprint", targeting it is likely to be the most direct way to stop that tumor's growth.

Because PDX models are able to retain the original tumor's genomic signature, **they are a critical tool in helping us design new drugs that target genomic driver alterations.**

HELP WANTED

New PDX models needed!

For each new driver alteration identified, multiple new PDX models are needed.

Driver alterations are often found across multiple tumor types and may also have different genomic sub-variants.

Genomic driver alteration

NRG1 Fusions

10+ solid tumor types

Fusion partners & variants

Collaborations to build libraries of PDX models for each new driver alteration will be key in advancing the development of new precision medicines for cancer.

ELEVATION ONCOLOGY

Learn more at elevationoncology.com